查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190984

全球自動化止血設備市場——增長、趨勢和預測 (2023-2028)

Fully Automated Coagulometer Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，全球自動化凝血測試設備市場預計將以 8.2% 的複合年增長率增長。

主要亮點

  • 大流行的爆發影響了全自動凝血測試設備市場。 在大流行期間，血液相關疾病增加，因為許多人被確認患有 COVID-19 血液病。 例如，根據 NCBI 於 2021 年 11 月發表的一項研究，一些 COVID-19 患者會出現涉及最小血管的異常血塊。 血塊也可能在身體的多個部位形成，包括肺部。 這種異常的凝塊會導致多種並發症，包括器官損傷、心肌梗塞和中風。
  • 因此，大流行早期血液相關疾病病例的增加加速了對全自動凝血儀的需求，這是診斷血液相關疾病的基本要求之一。 因此，預計今年市場將再次大幅增長，並有望在預測期內繼續保持上升趨勢。
  • 血液相關疾病負擔的增加是市場的主要驅動力之一。 例如，白血病和淋巴瘤協會（LLS）在 2021 年發布的一份報告估計，美國每年大約每三分鐘就會有一個人被診斷出患有白血病、淋巴瘤和骨髓瘤，估計全美共有 186,400 人。到 2021 年在美國。被診斷出患有白血病、淋巴瘤和骨髓瘤。 據估計，2021 年美國將有 34,920 人（19,320 名男性和 15,600 名女性）新診斷出患有骨髓瘤。
  • 此外，NIH 於 2022 年 4 月發表的一項研究發現，到 2020 年，團圓血症將導致 474,519 人發病和 311,594 人死亡，導致全球癌症發病率和癌症相關死亡。據估計，團聚血症是導致癌症死亡的第 15 位和第 11 位最常見原因 因此，此類案例有望推動對自動凝血儀的需求，因為它們是管理血液相關疾病的關鍵要求之一。
  • 創新的新產品發布預計也將推動市場增長。 例如，2021 年 10 月，Trivitron Healthcare 推出了由 Diagon Ltd. 製造的新系列凝血分析儀。 在兩家公司簽署合作協議後，Trivitron 與 Diagon-Vanguard Diagnostics India 宣佈在印度診斷市場推出這些產品。
  • 新產品是 Diagon Hungary COAG 系列的自動/半自動 POC 系統，用於降低大手術中的出血風險以及監測止血治療和抗凝劑的效果。 因此，此類創新可以在市場上創造新的機會並鼓勵許多新進入者。 因此，預計在預測期內將出現可觀的市場增長。
  • 但是，在預測期內，高昂的測試成本可能會抑制市場增長。

全自動凝血檢測儀的市場趨勢

醫院部門預計在預測期內將顯著增長

  • 醫院配備了用於診斷、外科手術和改進治療的先進技術設備。 由於血液病的診斷和手術數量不斷增加，醫院部門正在經歷快速增長。 預計這一趨勢將在預測期內繼續，推動該行業的增長。
  • 隨著新興國家/地區醫院數量的增加，這對全自動凝血分析儀的需求產生了積極影響。 例如，根據美國醫院協會2021年年度調查，2020年全美共有超過1805家農村社區醫院、3336家城市社區醫院和3453家系統中的社區醫院。 此外，到 2021 年，美國所有醫院的住院總人數將超過 36,241,815 人。
  • 同樣，根據 CCDEP（疾病動態、經濟和政策中心）2021 年 4 月的報告，全國共有 25,778 家公立醫院，其中公立醫院最多的邦是北方邦 (4,635)、卡納塔克邦 ( 2,842）、拉賈斯坦邦（2,850）、奧裡薩邦（1,806）和西孟加拉邦。 醫院憑藉其低廉的手術和藥物成本以及最先進的基礎設施，已成為世界領先的血液相關疾病護理中心。 醫院提供從診斷到治療再到治療後的一貫服務，無論採用何種診療方式，都是患者的首選。 因此，醫院數量的增加將導致患者數量的增加，這有望對該行業產生積極影響。
  • 因此，由於上述因素，該細分市場有望在預測期內實現大幅增長。

預計在預測期內北美將顯著增長

  • 預計在預測期內，北美將主導整個自動化混凝劑市場。 這種增長是由血液病病例數量增加和該地區主要參與者推出新產品線等因素推動的。 例如，根據英國貧血和淋巴瘤協會 (LLS) 於 2021 年發布的一份報告，美國 2021 年估計的 1,898,160 例新癌症病例中約有 9.8% 來自貧血、淋巴瘤和骨髓瘤.據說被佔用
  • 同樣，根據加拿大癌症協會2022年5月發布的一份報告，2022年將有大約6700名加拿大人、4000名男性和1800人死於團圓血症。據說 因此，此類案例表明對全自動凝血檢測設備的需求將會增加，這可能會推動北美地區的市場增長。
  • 主要產品的發布、市場參與者和製造商的高度集中、主要參與者之間的收購和合作以及美國血液相關疾病病例的增加是推動該國全自動凝血儀市場增長的因素。部分 例如，根據英國貧血和淋巴瘤協會（LLS）2021年發表的一份報告，在美國（US），英國貧血、淋巴瘤、骨髓瘤、骨髓增生異常綜合徵（MDS）、骨髓增生性腫瘤（估計有1,519,907患有 MPN 或處於緩解期的人。 另據報導，2021 年美國約有 90,390 人被診斷出患有淋巴瘤（8,830 人為霍奇金淋巴瘤，81,560 人為非霍奇金淋巴瘤）。
  • 因此，由於上述因素，所研究的市場預計將在北美地區增長。

自動凝血儀市場競爭分析

全自動血液凝固設備市場由幾家主要參與者組成和整合。 公司的產品發布和戰略聯盟預計將推動自動化混凝劑市場的增長。 競爭格局包括 HemoSonics LLC、Siemens Healthcare、Abbott Laboratories、F. Hoffmann-La Roche Ltd、Erba Group、Werfen、Horiba、Haemonetics Corporation 和 Maccura Biotechnology，以及一些具有市場份額的知名國際和本地公司。包括分析.

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 血液相關疾病的負擔不斷增加
    • 新產品趨勢
  • 市場製約因素
    • 飆升的檢驗成本
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按產品類型
    • 凝血系統
    • 消耗品
    • 配飾
  • 最終用戶
    • 醫院
    • 診斷機構
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Maccura Biotechnology Co. Ltd
    • Siemens Healthcare
    • Werfen
    • Horiba
    • Haemonetics Corporation
    • HemoSonics LLC
    • F. Hoffmann-La Roche Ltd
    • Erba Group
    • Diagon
    • iLine Microsystems SL

第7章 市場機會今後動向

簡介目錄
Product Code: 68380

The fully automated coagulometer market is expected to register a CAGR of 8.2% over the forecast period.

Key Highlights

  • The outbreak of the pandemic impacted the fully automated coagulometer market. Blood-related diseases increased during the pandemic as many people were seen to acquire hematologic disorders along with COVID-19. For instance, as per the NCBI study published in November 2021, some people with COVID-19 develop abnormal blood clots, including in the smallest blood vessels. Clots can also form in multiple places in the body, including the lungs. This abnormal clotting can cause a variety of complications, including organ damage, heart attack, and stroke.
  • Thus, increasing cases of blood-related diseases in the initial days of the pandemic accelerated the demand for fully automated coagulometers, as it is one of the essential requirements for the diagnosis of blood-related diseases. Therefore, the market is anticipated to witness considerable growth in the current year and is expected to continue the upward trend over the forecast period.
  • The growing burden of blood-related diseases is one of the major drivers for the market. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, approximately every three minutes, one person in United States is diagnosed with leukemia, lymphoma, or myeloma every year and an estimated combined total of 186,400 people in United States were diagnosed with leukemia, lymphoma or myeloma in 2021. The report also stated an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were diagnosed in United States in 2021.
  • Furthermore, per the NIH study published in April 2022, leukemia was estimated to be the 15th and 11th most frequent cause of cancer incidence and cancer-related mortality globally, accounting for 474,519 incident cases and 311,594 deaths in 2020. Therefore, such instances are anticipated to propel the demand for automated coagulometers as it is one of the key requirements for managing blood-related diseases.
  • The launch of new innovative products is also anticipated to propel market growth. For instance, in October 2021, Trivitron Healthcare launched a new range of coagulation analyzer products manufactured by Diagon Ltd. Trivitron, in collaboration with Diagon-Vanguard Diagnostics India, announced the launch of these products in the Indian diagnostic market following the signing of a collaboration agreement between the companies.
  • New products include automated, semi-automated, and POC systems of the COAG series manufactured by Diagon Hungary to reduce the risk of bleeding in major surgeries and monitor the effectiveness of hemostatic therapies and anticoagulant drugs. Therefore, such innovations may create new opportunities for the market, which may encourage many new players to enter the market. Thus, considerable market growth is expected over the forecast period.
  • However, the high cost of the test is likely to restrain the market growth over the forecast period.

Fully Automated Coagulometer Market Trends

Hospital Segment Expected to Witness Considerable Growth Over the Forecast Period

  • Hospitals are well-equipped with advanced technological equipment for diagnostic and surgical procedures and improved treatments. The hospital segment is witnessing rapid growth, owing to the growing number of diagnostic and surgeries due to blood-related diseases. This trend is expected to continue over the forecast period, driving growth in the segment.
  • With the rising number of hospitals across developing countries, there is a positive impact on the demand for fully automated coagulometers. For instance, according to the American Hospital Association annual survey 2021, in United States, there were more than 1,805 rural community hospitals, 3,336 urban community hospitals, and 3,453 community hospitals in the system in 2020. Moreover, total admissions in all United States hospitals were more than 36,241,815 in 2021.
  • Similarly, as per the April 2021 report of the Center for Disease Dynamics, Economics and Policy (CCDEP), there were 25,778 public sector hospitals in the country, and the states with the highest number of public hospitals were Uttar Pradesh (4,635), Karnataka (2,842), Rajasthan (2,850), Odisha (1,806), and West Bengal. Hospitals are the major treatment centers for blood-related diseases globally, owing to the low cost of surgeries and medication and the availability of state-of-art infrastructure. Hospitals offer integrated services from diagnostics to treatment and treatment to post-treatment, which is patients' first choice for any diagnostic and treatment procedure. Thus increasing the number of hospitals may increase the number of patients, which is expected to positively impact the segment.
  • Therefore, owing to the abovementioned factors, the segment is anticipated to witness considerable growth over the forecast period.

North America Expected to Witness Significant Growth Over the Forecast Period

  • North America is expected to dominate the overall fully automated coagulometer market over the forecast period. The growth is due to factors such as the rising cases of blood-related diseases and the launch of new product lines by the key players in the region. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, new cases of leukemia, lymphoma, and myeloma accounted for around 9.8% of the estimated 1,898,160 new cancer cases in United States in 2021.
  • Similarly, as per the report published by the Canadian Cancer Society in May 2022, around 6,700 Canadians will be diagnosed with leukemia, 4,000 men will be diagnosed with leukemia, and 1,800 will die from it in 2022. Therefore, such instances indicate that the demand for fully automated coagulometers may increase, thereby propelling the market growth in the North American region.
  • Key product launches, high concentration of market players or manufacturer's presence, acquisition and & partnerships among major players, and rising cases of blood-related diseases in United States are some of the factors driving the growth of the fully automated coagulometer market in the country. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, an estimated 1,519,907 people in United States (US) were living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs) in 2021. The report also stated that around 90,390 people in United States were diagnosed with lymphoma in 2021 (8,830 cases of Hodgkin Lymphoma and 81,560 cases of Non-Hodgkin Lymphoma).
  • Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North America Region.

Fully Automated Coagulometer Market Competitive Analysis

The fully automated coagulometer market is consolidated and consists of a few major players. Product launches and strategic alliances by companies are expected to drive the fully automated coagulometer market growth. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known, including HemoSonics LLC, Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Erba Group, Werfen, Horiba, Haemonetics Corporation, and Maccura Biotechnology Co. Ltd, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Defination
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Blood Related Diseases
    • 4.2.2 Emerging Trends in Product
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Test
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Coagulation System
    • 5.1.2 Consumables
    • 5.1.3 Accessories
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Maccura Biotechnology Co. Ltd
    • 6.1.2 Siemens Healthcare
    • 6.1.3 Werfen
    • 6.1.4 Horiba
    • 6.1.5 Haemonetics Corporation
    • 6.1.6 HemoSonics LLC
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Erba Group
    • 6.1.9 Diagon
    • 6.1.10 iLine Microsystems SL

7 MARKET OPPORTUNITIES AND FUTURE TRENDS